期刊文献+

低分子肝素与普通肝素在脑血管病介入治疗中的应用效果观察 被引量:4

下载PDF
导出
摘要 目的对比低分子肝素与普通肝素在脑血管病介入治疗中的应用效果,为抗凝药物治疗提供参考。方法行PCI术的冠心病患者80例平均分为治疗组与对照组,各40例,治疗组采用依诺肝素皮下注射抗凝治疗,对照组给予普通肝素皮下注射抗凝治疗。结果经过观察测定,对照组在5min、60min、120min时的活化凝血时间分别为(371±39)s、(332±34)s、(258±39)s,而对照组在5min、60min、120min时的ACT时间分别为(256±32)s、(201±32)s、(159±32)s。治疗组患者在各个时间点的活化凝血时间都明显少于对照组,差异有统计学意义(P均<0.05)。经过治疗3个月后的预后观察,两组均无死亡患者。治疗组并发血肿1例,出血1例;对照组并发血肿5例,出血4例,血栓形成3例,心肌梗死与血运重建各2例。治疗组各种并发症发生情况都明显少于对照组,差异有统计学意义(P均<0.05)。结论相对于普通肝素来说,低分子肝素在脑血管病介入治疗中的应用可有效降低各个时间点的活化凝血时间,且预后并发症少,值得推广应用。
作者 杨睿海
出处 《海南医学》 CAS 2011年第20期33-34,共2页 Hainan Medical Journal
  • 相关文献

参考文献6

  • 1刘泽霖,贺石林,李家增.血栓性疾病的诊断与治疗[M].北京:人民卫生出版杜,2010: 61-72.
  • 2贾三庆,王雷,严松彪,邢云利,赵敏,陈辉,王永亮.冠脉介入治疗患者联合应用低分子肝素和普通肝素的抗凝效果研究[J].全科医学临床与教育,2004,2(1):14-17. 被引量:5
  • 3陈纪林,陈珏,乔树宾,吴永健,戴军,袁晋青,秦学文,姚民,杨跃进,高润霖.冠心病介入治疗中应用低分子肝素与普通肝素的随机对照研究[J].中华心血管病杂志,2006,34(2):127-129. 被引量:17
  • 4Chen WH, Lan CP, Lan NG, et al. Stable and optimal anticoagulation is achieved with asingle dose of intravenous enoxaparin in patients undergoing percutaneouscoronary intervention[J]. J Invasive Cardiol, 2002, 14(8): 439-442.
  • 5Molitemo DJ, Hermiller JB, Kereiakes D J, et al, et al. A novel point of gale enoxapalion monitor for use during PCh results of the ELECT study[J]. J Am Coil Cardiol, 2009, 42(6): 1132-1139.
  • 6Antman L, Handin R. Low molecular weight heparins: an intriguing new twist with profound implications[J]. Cimlation, 2008, 98(6):287-289.

二级参考文献12

  • 1[1]Marc Cohen,Christine Demers,Enrique P.Gurfinkel,et,al,The Efficacy and Safety of Subcutaneous Enoxaparin in Non-Qwave Coronary Events,N Eng J Med,1997,337:447-452.
  • 2[2]Elliott M.Antman,Carolyn H.Mc Cabe,Gurfinkel,et al.Enoxaparin prevents death and cardiac ischemia events in unstable angina/non-Q-wave myocardial infarction:results of Thrombolysis In Myocardial Infarction (TIMI-1lB) trial.Circtlation.1999,100:1593-1601.
  • 3[3]J.Ph.Collet,Montalescot,Lison,et al.Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment In Patients with Unstable Angina Pectoris.Circulation.2001,103:658-663.
  • 4[4]Elliott,Antman,Marc Cohen,David Radley,et al.Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction:TIMI-1lB-ESSENCE meta-analysis.Circulation.1999,100:1602-1608.
  • 5Cohen M,Demers C,Gurfinkel EP,et al.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.N Engl J Med,1997,337:447-452.
  • 6Antman EM,McCabe CH,Gurfinkel EP,et al.Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction.Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.Circulation,1999,100:1593-1601.
  • 7Serebruany VL,Malinin AI,Callahan KP,et al.Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction:the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.Am Heart J,2003,145:636-642.
  • 8Wallentin L,Goldstein P,Armstrong PW,et al.Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting:the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.Circulation,2003,108:135-142.
  • 9Collet JP,Montalescot G,Lison L,et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.Circulation,2001,103:658-663.
  • 10Kereiakes DJ,Montalescot G,Antman EM,et al.Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention:an expert consensus.Am Heart J,2002,144:615-624.

共引文献20

同被引文献38

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部